Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease

View Full Paper

Ask AI

Bookmark

The study shows a significant difference in event-free survival with mitoxantrone outperforming liposomal daunorubicin in children.
Event-free survival at five years for mitoxantrone was 71.9%, compared to 56.6% for liposomal daunorubicin, highlighting its efficacy.
Randomized trial compared mitoxantrone and liposomal daunorubicin, evaluating their impact on measurable residual disease post induction therapy and hSCT usage for high-risk patients with AML and MRD evaluation in pediatric patients after induction 1 or induction 2 therapy sessions. The analysis indicated that effective risk stratification and timely transplants greatly enhance outcomes for patients, particularly those categorized as high-risk due to elevated MRD rates on follow-up after initial treatment initiation steps after induction therapy and the associated interventions such as hSCT. The 5-year overall survival rate also favored mitoxantrone with 88.6% compared to 76.2% for liposomal daunorubicin in standard-risk patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Randomized trial compares induction therapies for pediatric AML, showing mitoxantrone has superior outcomes.

Tierens et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark